Department of General Medical Oncology & Laboratory of Experimental Oncology, University Hospitals Leuven, Leuven Cancer Institute, Catholic University Leuven, Leuven, Belgium.
Expert Rev Anticancer Ther. 2012 Jun;12(6):711-23. doi: 10.1586/era.12.41.
Patients with advanced metastatic soft tissue sarcoma (STS) have a poor prognosis, and in the last two decades of the 20th century their overall survival has remained unchanged. Improved treatments are needed for these patients and for preventing metastases in earlier stages of disease. Numerous novel agents and new combination regimens are undergoing clinical testing in STS. Some of these agents show promising activity. Pazopanib is one such agent that has undergone Phase II and III evaluations in advanced STS. Pazopanib is a multi-tyrosine kinase inhibitor, blocking various signaling pathways, thereby preventing angiogenesis and metastasis, and inhibiting tumor cell growth and survival. In a Phase II study, pazopanib demonstrated activity in patients with advanced leiomyosarcomas, synovial sarcomas and other eligible STSs. This activity was confirmed in a Phase III trial, where pazopanib significantly extended the median progression-free survival versus placebo in a variety of STS subtypes.
晚期转移性软组织肉瘤（STS）患者预后不良，在 20 世纪的最后二十年中，他们的总生存率保持不变。这些患者需要更好的治疗方法，并且需要在疾病的早期阶段预防转移。目前正在对 STS 进行大量新型药物和新联合方案的临床试验。其中一些药物显示出了有希望的活性。帕唑帕尼就是这样一种在晚期 STS 中进行了 II 期和 III 期评估的药物。帕唑帕尼是一种多酪氨酸激酶抑制剂，可阻断多种信号通路，从而防止血管生成和转移，并抑制肿瘤细胞生长和存活。在一项 II 期研究中，帕唑帕尼在晚期平滑肌肉瘤、滑膜肉瘤和其他符合条件的 STS 患者中显示出了活性。这一活性在 III 期试验中得到了证实，帕唑帕尼在各种 STS 亚型中显著延长了中位无进展生存期，优于安慰剂。
